Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
6.93B | 7.54B | 10.02B | 6.96B | 5.04B | 5.27B | Gross Profit |
2.28B | 2.67B | 5.03B | 2.61B | 1.49B | 1.81B | EBIT |
762.00M | 1.13B | 3.51B | 1.20B | 190.00M | 746.00M | EBITDA |
1.40B | 1.71B | 4.06B | 1.93B | 711.00M | 1.19B | Net Income Common Stockholders |
187.00M | 273.00M | 953.00M | 88.00M | -173.00M | 158.00M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
1.86B | 1.57B | 1.56B | 1.14B | 1.06B | 878.00M | Total Assets |
15.69B | 12.89B | 13.09B | 12.26B | 11.08B | 10.63B | Total Debt |
8.29B | 1.05B | 3.96B | 4.61B | 4.44B | 4.21B | Net Debt |
6.94B | 516.00M | 3.19B | 4.10B | 3.83B | 3.93B | Total Liabilities |
11.53B | 6.53B | 7.24B | 7.98B | 7.32B | 6.75B | Stockholders Equity |
2.26B | 2.78B | 2.46B | 1.54B | 1.40B | 1.55B |
Cash Flow | Free Cash Flow | ||||
783.00M | 1.04B | 1.46B | 497.00M | 290.00M | 491.00M | Operating Cash Flow |
1.48B | 1.82B | 2.21B | 1.11B | 917.00M | 1.07B | Investing Cash Flow |
-668.00M | -1.10B | -748.00M | -830.00M | -398.00M | -480.00M | Financing Cash Flow |
-891.00M | -931.00M | -1.16B | -403.00M | -192.00M | -510.00M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | 415.15M | 9.94 | 10.05% | -10.12% | 5.34% | ||
76 Outperform | 1.17B | 12.40 | 3.41% | 0.19% | 19.24% | ||
74 Outperform | 739.92M | 10.93 | 2.52% | 15.45% | 26.50% | ||
73 Outperform | 3.78B | 63.04 | 0.77% | 54.19% | 28.29% | ||
71 Outperform | 8.63B | 14.33 | 5.77% | 0.74% | -4.29% | -24.35% | |
51 Neutral | $2.02B | -1.19 | -21.37% | 3.64% | 2.88% | -30.57% |
Israel Corp has announced that a statement of claims has been filed against Mr. Yaakov Amidror, an external director at the company, by the Securities Authority. This is in relation to his role as chairman of the board at Next Gen Biomed Ltd. The company clarified that it has no connection to Next Gen Biomed Ltd or the ongoing administrative enforcement procedure.